MUC5AC Radionuclide Antibody Composition for Reduced Container Adsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The formulation of radionuclide-labeled antibodies that specifically bind to mucin subtype 5AC faces issues with radioactivity adsorption to storage containers, affecting the stability and efficacy of the preparation.
Innovation Solution
A liquid pharmaceutical composition containing a radionuclide-antibody conjugate with specific concentrations of L-arginine, L-histidine, and a surfactant is formulated to reduce radioactivity adsorption to storage containers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If radionuclide-labeled antibody is formulated in liquid form, then the pharmaceutical composition can be administered conveniently, but radioactivity adsorption to storage containers occurs affecting stability and efficacy
Solution Approach 1:
The patent introduces an intermediary substance (surfactant or polymer) that mediates between the radionuclide-antibody conjugate and the storage container. This intermediary forms a protective layer or modifies the surface properties, preventing direct adsorption of the radioactive conjugate to the container while maintaining the liquid formulation's administrability.
Solution Approach 2:
The patent changes physical or chemical parameters of the formulation, such as adjusting pH, ionic strength, or adding stabilizing agents, to modify the interaction between the radionuclide-antibody conjugate and the storage container. These parameter changes reduce adsorption while preserving the liquid form's convenience for administration.
2Quantity of substance
If antibody concentration is increased to improve efficacy, then therapeutic effect is enhanced, but radioactivity adsorption to storage containers increases
Solution Approach 1:
The intermediary substance (surfactant or polymer) acts as a mediator that allows higher antibody concentrations to be formulated without proportionally increasing adsorption. The intermediary forms a protective interface that decouples the relationship between antibody concentration and adsorption, enabling efficacy enhancement while maintaining radioactivity stability.
Solution Approach 2:
The patent modifies formulation parameters such as pH, ionic strength, or the addition of stabilizing agents to enable higher antibody concentrations without increasing adsorption. These parameter changes allow the system to maintain both high efficacy (high antibody concentration) and high reliability (stable radioactivity).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a stable liquid pharmaceutical composition with reduced radioactivity adsorption, ensuring consistent quality and efficacy.
Implementation Method 1
the radioactive anti-MUC5AC specific antibody can be stabilized by using a specific amino acid
Implementation Method 2
the present inventors have found a new problem of adsorption of radioactivity to storage containers
Data Source
Figure 1A~2
Figure 3
AI summary
The present invention relates to a liquid pharmaceutical composition containing a conjugate of a radionuclide and an antibody as an active ingredient. It is characterized in that the antibody is an antibody that specifically binds to mucin subtype 5AC, the concentration of the aforementioned antibody in the composition is 0.1 mg/mL or more and 5 mg/mL or less, and the composition contains L-arginine, L-histidine, and a surfactant. Such pharmaceutical composition shows reduced radioactivity adsorption to a storage container.